



AI for Change:

AI's purpose in an uncertain world


October 2022



What is our legacy?



The exponential speed of AI



**Technology is neither good
nor bad; *nor is it neutral.***

Melvin Kranzberg


Feeding large populations



Protecting Coral Reefs



Reducing Carbon Emissions



Responsible AI



AI and retina scanning for Alzheimer's detection



A framework for change

Bold idea



**Outcome
focused**



Collaboration



**Responsible
AI**




**Courageous
Leaders**



Meet Melissa





SEPTEMBER 23, 2020

Accenture Puts Data Science to Work for Pediatric Leukemia Research

NEW YORK; Sept. 23, 2020 – Accenture (NYSE: ACN) today announced that it has built a data and analytics approach to manage and derive insights from pediatric acute myeloid leukemia (AML) genomic data. Working in collaboration with researchers and clinicians from [Fred Hutchinson Cancer Research Center](#) (Fred Hutch), and the [Target Pediatric AML \(TpAML\)](#) computational working group, a large-scale research project which supplied the data, this new approach aims to enable pediatric oncology physicians and researchers — specifically those focused on pediatric AML — to better analyze patient clinical trial and genetic data, with the potential to improve [precision medicine](#).

What's our legacy?